Physician profile
Amy Grafa
NPI 1922777838
$7,294.84
in general payments reported to CMS, 2019-2025
51 companies · $2,295 in 2025
The $2,295 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $1,600 · 2023: $1,628 · 2024: $1,587 · 2025: $2,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,510.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.27 | 2022-2025 | |
| Genzyme Corporation | $645.33 | 2023-2025 | |
| Janssen Biotech, INC. | $419.47 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $381.97 | 2022-2025 | Taltz, Mounjaro, Ebglyss |
| Galderma Laboratories, L.P. | $329.05 | 2024-2025 | Nemluvio, Dysport, Aklief |
| Sun Pharmaceutical Industries INC. | $313.41 | 2023-2025 | Blu-U |
| Pfizer INC. | $311.83 | 2022-2025 | |
| Amgen INC. | $296.93 | 2021-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $289.54 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Arcutis Biotherapeutics, INC. | $275.04 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $268.60 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.99 | 2023-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $227.04 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Corium, LLC | $192.38 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $170.05 | 2022-2023 | Farxiga, Fasenra |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $132.05 | 2023-2025 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $120.52 | 2021-2023 | Trintellix |
| Leo Pharma INC. | $119.46 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $119.26 | 2023-2025 | Bimzelx, Cimzia |
| Abbott Laboratories | $110.34 | 2022-2023 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.66 | 2022-2024 | Spevigo, Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.66 | 2022 | |
| Almirall LLC | $80.54 | 2025 | Klisyri, Seysara |
| Biofrontera INC. | $72.68 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $66.47 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $59.27 | 2021-2023 | Rexulti |
| Dermavant Sciences, INC. | $58.56 | 2024 | Vtama |
| Kowa Pharmaceuticals America, INC. | $49.32 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.60 | 2022-2023 | Spravato |
| Dexcom, INC. | $42.11 | 2022-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $39.01 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Tris Pharma INC | $37.27 | 2023 | Dyanavel Xr |
| Exact Sciences Corporation | $36.02 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $34.15 | 2022 | |
| Paratek Pharmaceuticals, INC. | $34.15 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $28.33 | 2022 | |
| Organon LLC | $27.35 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $27.03 | 2023 | Sotyktu |
| Kerecis Limited | $24.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Eisai INC. | $24.12 | 2021 | |
| Amarin Pharma, INC. | $22.38 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.88 | 2023 | |
| Journey Medical Corporation | $19.09 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $17.71 | 2025 | Neo-Synalar, Clindacin Etz |
| Teva Pharmaceuticals USA, INC. | $16.87 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.78 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $13.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.03 | 2022 | |
| Lundbeck LLC | $12.92 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Grafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.